Cargando…

Added diagnostic value of routinely measured hematology variables in diagnosing immune checkpoint inhibitor mediated toxicity in the emergency department

BACKGROUND: Immune checkpoint inhibitors (ICI) show remarkable results in cancer treatment, but at the cost of immune‐related adverse events (irAE). irAE can be difficult to differentiate from infections or tumor progression, thereby challenging treatment, especially in the emergency department (ED)...

Descripción completa

Detalles Bibliográficos
Autores principales: Niemantsverdriet, Michael S. A., Vrijsen, Bram E. L., Visser ’t Hooft, Therese, Suijkerbuijk, Karijn P. M., van Solinge, Wouter W., ten Berg, Maarten J., Haitjema, Saskia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278460/
https://www.ncbi.nlm.nih.gov/pubmed/37076947
http://dx.doi.org/10.1002/cam4.5956
_version_ 1785060490458693632
author Niemantsverdriet, Michael S. A.
Vrijsen, Bram E. L.
Visser ’t Hooft, Therese
Suijkerbuijk, Karijn P. M.
van Solinge, Wouter W.
ten Berg, Maarten J.
Haitjema, Saskia
author_facet Niemantsverdriet, Michael S. A.
Vrijsen, Bram E. L.
Visser ’t Hooft, Therese
Suijkerbuijk, Karijn P. M.
van Solinge, Wouter W.
ten Berg, Maarten J.
Haitjema, Saskia
author_sort Niemantsverdriet, Michael S. A.
collection PubMed
description BACKGROUND: Immune checkpoint inhibitors (ICI) show remarkable results in cancer treatment, but at the cost of immune‐related adverse events (irAE). irAE can be difficult to differentiate from infections or tumor progression, thereby challenging treatment, especially in the emergency department (ED) where time and clinical information are limited. As infections are traceable in blood, we were interested in the added diagnostic value of routinely measured hematological blood cell characteristics in addition to standard diagnostic practice in the ED to aid irAE assessment. METHODS: Hematological variables routinely measured with our hematological analyzer (Abbott CELL‐DYN Sapphire) were retrieved from Utrecht Patient Oriented Database (UPOD) for all patients treated with ICI who visited the ED between 2013 and 2020. To assess the added diagnostic value, we developed and compared two models; a base logistic regression model trained on the preliminary diagnosis at the ED, sex, and gender, and an extended model trained with lasso that also assessed the hematology variables. RESULTS: A total of 413 ED visits were used in this analysis. The extended model showed an improvement in performance (area under the receiver operator characteristic curve) over the base model, 0.79 (95% CI 0.75–0.84), and 0.67 (95% CI 0.60–0.73), respectively. Two standard blood count variables (eosinophil granulocyte count and red blood cell count) and two advanced variables (coefficient of variance of neutrophil depolarization and red blood cell distribution width) were associated with irAE. CONCLUSION: Hematological variables are a valuable and inexpensive aid for irAE diagnosis in the ED. Further exploration of the predictive hematological variables could yield new insights into the pathophysiology underlying irAE and in distinguishing irAE from other inflammatory conditions.
format Online
Article
Text
id pubmed-10278460
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-102784602023-06-20 Added diagnostic value of routinely measured hematology variables in diagnosing immune checkpoint inhibitor mediated toxicity in the emergency department Niemantsverdriet, Michael S. A. Vrijsen, Bram E. L. Visser ’t Hooft, Therese Suijkerbuijk, Karijn P. M. van Solinge, Wouter W. ten Berg, Maarten J. Haitjema, Saskia Cancer Med RESEARCH ARTICLES BACKGROUND: Immune checkpoint inhibitors (ICI) show remarkable results in cancer treatment, but at the cost of immune‐related adverse events (irAE). irAE can be difficult to differentiate from infections or tumor progression, thereby challenging treatment, especially in the emergency department (ED) where time and clinical information are limited. As infections are traceable in blood, we were interested in the added diagnostic value of routinely measured hematological blood cell characteristics in addition to standard diagnostic practice in the ED to aid irAE assessment. METHODS: Hematological variables routinely measured with our hematological analyzer (Abbott CELL‐DYN Sapphire) were retrieved from Utrecht Patient Oriented Database (UPOD) for all patients treated with ICI who visited the ED between 2013 and 2020. To assess the added diagnostic value, we developed and compared two models; a base logistic regression model trained on the preliminary diagnosis at the ED, sex, and gender, and an extended model trained with lasso that also assessed the hematology variables. RESULTS: A total of 413 ED visits were used in this analysis. The extended model showed an improvement in performance (area under the receiver operator characteristic curve) over the base model, 0.79 (95% CI 0.75–0.84), and 0.67 (95% CI 0.60–0.73), respectively. Two standard blood count variables (eosinophil granulocyte count and red blood cell count) and two advanced variables (coefficient of variance of neutrophil depolarization and red blood cell distribution width) were associated with irAE. CONCLUSION: Hematological variables are a valuable and inexpensive aid for irAE diagnosis in the ED. Further exploration of the predictive hematological variables could yield new insights into the pathophysiology underlying irAE and in distinguishing irAE from other inflammatory conditions. John Wiley and Sons Inc. 2023-04-19 /pmc/articles/PMC10278460/ /pubmed/37076947 http://dx.doi.org/10.1002/cam4.5956 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Niemantsverdriet, Michael S. A.
Vrijsen, Bram E. L.
Visser ’t Hooft, Therese
Suijkerbuijk, Karijn P. M.
van Solinge, Wouter W.
ten Berg, Maarten J.
Haitjema, Saskia
Added diagnostic value of routinely measured hematology variables in diagnosing immune checkpoint inhibitor mediated toxicity in the emergency department
title Added diagnostic value of routinely measured hematology variables in diagnosing immune checkpoint inhibitor mediated toxicity in the emergency department
title_full Added diagnostic value of routinely measured hematology variables in diagnosing immune checkpoint inhibitor mediated toxicity in the emergency department
title_fullStr Added diagnostic value of routinely measured hematology variables in diagnosing immune checkpoint inhibitor mediated toxicity in the emergency department
title_full_unstemmed Added diagnostic value of routinely measured hematology variables in diagnosing immune checkpoint inhibitor mediated toxicity in the emergency department
title_short Added diagnostic value of routinely measured hematology variables in diagnosing immune checkpoint inhibitor mediated toxicity in the emergency department
title_sort added diagnostic value of routinely measured hematology variables in diagnosing immune checkpoint inhibitor mediated toxicity in the emergency department
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278460/
https://www.ncbi.nlm.nih.gov/pubmed/37076947
http://dx.doi.org/10.1002/cam4.5956
work_keys_str_mv AT niemantsverdrietmichaelsa addeddiagnosticvalueofroutinelymeasuredhematologyvariablesindiagnosingimmunecheckpointinhibitormediatedtoxicityintheemergencydepartment
AT vrijsenbramel addeddiagnosticvalueofroutinelymeasuredhematologyvariablesindiagnosingimmunecheckpointinhibitormediatedtoxicityintheemergencydepartment
AT visserthoofttherese addeddiagnosticvalueofroutinelymeasuredhematologyvariablesindiagnosingimmunecheckpointinhibitormediatedtoxicityintheemergencydepartment
AT suijkerbuijkkarijnpm addeddiagnosticvalueofroutinelymeasuredhematologyvariablesindiagnosingimmunecheckpointinhibitormediatedtoxicityintheemergencydepartment
AT vansolingewouterw addeddiagnosticvalueofroutinelymeasuredhematologyvariablesindiagnosingimmunecheckpointinhibitormediatedtoxicityintheemergencydepartment
AT tenbergmaartenj addeddiagnosticvalueofroutinelymeasuredhematologyvariablesindiagnosingimmunecheckpointinhibitormediatedtoxicityintheemergencydepartment
AT haitjemasaskia addeddiagnosticvalueofroutinelymeasuredhematologyvariablesindiagnosingimmunecheckpointinhibitormediatedtoxicityintheemergencydepartment